EUnetHTA21 starts preparation for joint HTA from 2024
After several years of discussions, the EU will start to conduct joint HTAs in 2024. This process will be organized and overseen
Category: News and updates
ITC was accepted and improved additional benefit rating
In the recent early benefit assessment of nivolumab, the G-BA not only accepted the submitted ITC, but this also resulted in a
First COVID-19 drug has been assessed by G-BA
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
What is reference pricing?
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
When can an off-label drug be the appropriate comparator therapy?
This question was discussed at the recent G-BA meeting on 2 September 2021. Previously, the G-BA had decided on the following procedural